Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Sotalol hydrochloride
Waymade Healthcare Plc
C07AA07
Sotalol hydrochloride
40mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02040000
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have further questions, please ask your doctor or your pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See Section 4. IN THIS LEAFLET: 1. What Sotalol Tablets are and what they are used for 2. What you need to know before you take Sotalol Tablets 3. How to take Sotalol Tablets 4. Possible side effects 5. How to store Sotalol Tablets 6. Contents of the pack and further information 1. WHAT SOTALOL TABLETS ARE AND WHAT THEY ARE USED FOR Sotalol Tablets contain the active ingredient Sotalol. Sotalol belongs to a group of drugs called beta-adrenergic blocking agents or “beta-blockers.” Sotalol is used to treat irregular heartbeats. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE SOTALOL TABLETS Do not take Sotalol Tablets: • if you are ALLERGIC to sotalol hydrochloride or any of the other ingredients in this medicine (listed in section 6). • if you suffer from ASTHMA, attacks of wheezing or any other lung disease. • if you have a very slow heart beat or LOW BLOOD PRESSURE. • if you suffer from a condition causing discolouration (white or purple) of the hands and feet (Raynaud’s syndrome). • if you suffer from any severe CIRCULATION DISORDERS. • if you have suffered from HEART DISEASE (such as untreated heart failure) or had a recent heart attack that your doctor does not know about. • if you suffer from a condition called METABOLIC ACIDOSIS. • if you suffer from an untreated tumour of the adrenal gland • if you suffer from KIDNEY FAILURE If you are affected by any of the above you should tell your doctor before taking this medicine. WARNINGS AND PRECAUTIONS Talk to your d Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Sotalol 40mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 40mg Sotalol hydrochloride For excipients: see 6.1 3. PHARMACEUTICAL FORM Tablet Round, white to off-white, flat bevelled edged tablets. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Sotalol 40mg Tablets are indicated for: _1. _ _VENTRICULAR ARRHYTHMIAS: _ • Treatment of life-threatening ventricular tachyarrhythmias; • Treatment of symptomatic non-sustained ventricular tachyarrhythmias _2. _ _SUPRAVENTRICULAR ARRHYTHMIAS: _ • Prophylaxis of paroxysmal atrial tachycardia, paroxysmal atrial fibrillation, paroxysmal A-V nodal re-entrant tachycardia, paroxysmal A-V re-entrant tachycardia using accessory pathways, and paroxysmal supraventricular tachycardia after cardiac surgery; • Maintenance of normal sinus rhythm following conversion of atrial fibrillation or atrial flutter 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology As with other antiarrhythmic agents, it is recommended that Sotalol 40mg Tablets be initiated and doses increased in a facility capable of monitoring and assessing cardiac rhythm. The dosage must be individualized and based on the patient's response. Proarrhythmic events can occur not only at initiation of therapy, but also with each upward dosage adjustment. In view of its β -adrenergic blocking properties, treatment with Sotalol 40mg Tablets should not be discontinued suddenly, especially in patients with ischaemic heart disease (angina pectoris, prior acute myocardial infarction) or hypertension, to prevent exacerbation of the disease (see 4.4 Warnings). The initiation of treatment or changes in dosage with sotalol should follow an appropriate medical evaluation including ECG control with measurement of the corrected QT interval, and assessment of renal function, electrolyte balance and concomitant medications (See 4.4 Warnings and precautions). Method of administration The following dosing schedule can be recommended: The ini Read the complete document